222 related articles for article (PubMed ID: 18833926)
1. [Clinical aspects of myeloproliferative disorders excluding CML].
Komatsu N
Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
[No Abstract] [Full Text] [Related]
2. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
3. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
4. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
5. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
6. Searching for CALRity in myeloproliferative neoplasms.
Cook JR
Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
[No Abstract] [Full Text] [Related]
7. Straightforward identification of masked polycythemia vera based on proposed revision of World Health Organization diagnostic criteria for BCR-ABL1-negative myeloproliferative neoplasms.
Chu D; Cho YU; Jang S; Seo EJ; Park CJ
Ann Lab Med; 2015 Nov; 35(6):651-3. PubMed ID: 26354357
[No Abstract] [Full Text] [Related]
8. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
[TBL] [Abstract][Full Text] [Related]
9. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Agarwal MB
J Assoc Physicians India; 2007 Jul; 55():507-10. PubMed ID: 17907502
[TBL] [Abstract][Full Text] [Related]
11. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
12. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
13. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
Cazzola M; Kralovics R
Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
[TBL] [Abstract][Full Text] [Related]
14. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Leone G; Foà R; Larocca LM
Blood; 2007 Nov; 110(9):3384-6. PubMed ID: 17644735
[TBL] [Abstract][Full Text] [Related]
15. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
Mesa RA
Curr Opin Hematol; 2008 Mar; 15(2):121-6. PubMed ID: 18300758
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
[TBL] [Abstract][Full Text] [Related]
18. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
Gotoh A; Komatsu N
Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
[No Abstract] [Full Text] [Related]
19. Chronic myeloproliferative diseases.
de Lacerda JF; Oliveira SN; Ferro JM
Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
[TBL] [Abstract][Full Text] [Related]
20. Quantification of JAK2V617F mutation by next-generation sequencing technology.
Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
[No Abstract] [Full Text] [Related]
[Next] [New Search]